Submission Details
Molecule(s):
CC(CCCN(C)CCO)Nc1ncnn2c(Br)ccc12
CCOC(=O)c1nc(N(C)C)c2ccc(Br)n2n1
CCOC(=O)c1nc(NC(C)=O)c2ccc(Br)n2n1
CCC(C)Oc1nc(C(N)=O)nn2c(F)ccc12
NC(=O)c1nc(O)c2ccc(F)n2n1
CN(CCO)CCCCNc1ncnn2c(F)ccc12
CCOC(=O)c1nc(N(C)C)c2ccc(F)n2n1
CCOC(=O)c1nc(NC(C)=O)c2ccc(F)n2n1
CCC(C)Oc1nc(C(N)=O)nn2c(Cl)ccc12
NC(=O)c1nc(O)c2ccc(Cl)n2n1
Design Rationale:
Remdesivir is a prodrug developed by Gilead Sciences as a treatment for Ebola virus disease and has shown very good success for the treatment of COVID 19 patients. Here are some ideas around Remdesivir analogues, simplifying it further and also combining it with functionalities present in other antiviral drugs and also other drugs which has shown promise for the treatment of COVID 19 patients like Favipiravir, Oseltamavir and hydroxychloroquine.
Other Notes:
Remdesivir analogues